The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not all comers.
ApexOnco Front Page
Recent articles
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
While Cogent joins the FGFR party.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
